SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tuck2/14/2018 12:41:48 PM
  Read Replies (1) of 3661
 
Galmed (GLMD) also cut more than in half by missing the primary endpoint in its proof of concept HIV-related NAFLD trial. A longer trial is ongoing in NASH, and is expected to read out next quarter. The company would like you to believe that the pathophysiology of the two indications is sufficiently different that the NASH trial still has a chance. They have about a year's worth of cash. I gather there's not much else in the pipeline. I'd be tempted to short a dead cat bounce.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News